Individualizing Biologic Therapy in IBD

In “Individualizing Biologic Therapy in IBD,” our panel explores the evolving treatment landscape in inflammatory bowel disease (IBD) and the clinical decision-making involved in selecting biologic therapies for individual patients. Expert faculty discuss how treatment selection is influenced by disease severity, symptom burden, disease characteristics, and the presence of complications such as stricturing or perianal Crohn’s disease. The panel also highlights the importance of initiating treatment early in the disease course to help prevent progression and long-term complications.

Throughout the discussion, expert faculty review the transition from conventional therapies, including mesalamine, corticosteroids, and immunomodulators, to advanced treatment approaches such as biologic therapies. The conversation emphasizes the rapidly evolving nature of IBD management, with expanding therapeutic classes and emerging clinical data continuing to reshape treatment strategies and improve patient outcomes. In addition, the panel examines the role of IL-23 inhibitors in the current treatment landscape, including considerations related to efficacy, safety, disease location, and route of administration.

Using a patient case discussion, expert faculty explain the rationale for selecting guselkumab for Crohn’s disease involving the small bowel and discuss the favorable safety profile associated with IL-23 inhibitors. The panel also reviews different induction and maintenance approaches, including intravenous and subcutaneous administration, and highlights how treatment decisions are individualized based on patient preferences, monitoring needs, and overall treatment goals in IBD.

Our next episode, “Overcoming Biologic Concerns and Achieving Remission in IBD,” features the panelists discussing patient experiences with starting biologic therapy for IBD, including concerns about safety, treatment monitoring, and long-term disease management. The panel also highlights how timely treatment adjustments and biologic therapy can improve symptom control, remission, and overall quality of life.